Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Recognizing warning signs of a bad cryptocurrency investment can save you from significant losses. Stay alert and informed with our guide.
19,013 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
NVIDIA continues to outpace AMD in data-center AI hardware even as a Kyber rack delay looms, reinforcing Nvidia’s moa...
Telehealth is changing how we get care—and how we invest. This article breaks down the growth story, uses Hims & Hers...
House Republicans rolled out a $95 billion budget blueprint aimed at defense, farming support, and stricter voter reg...
Lemonade posted first positive GAAP free cash flow in the latest quarter, a milestone that reshapes the insurtech nar...
Small-cap ETFs can boost growth, but choosing the right one matters. This guide breaks down ISCB and SCHA, showing ho...
Global dividend payments in Q3 2025 surged to a record, signaling the largest dividend payout history and fueling ren...
Two leading midstream ETFs, AMLP and MLPX, battle for income and tax efficiency as the 2026 energy rally persists. Th...
Bitwise CIO Matt Hougan rejects blame for Bitcoin's decline, framing it as a crypto winter phenomenon driven by risk ...
Intel stock looks beaten in the near term, but long-term possibilities remain. This guide breaks down the factors tha...
OpenAI says shares Anthropic’s red lines on how the military can use AI, signaling a rare cross-firm consensus that c...
Grief can be a doorway for financial scams. Learn how to spot red flags from a memorial business, guard your money, a...